PMID- 33448618
OWN - NLM
STAT- MEDLINE
DCOM- 20210922
LR  - 20210922
IS  - 1476-5829 (Electronic)
IS  - 1476-5810 (Print)
IS  - 1476-5810 (Linking)
VI  - 19
IP  - 1
DP  - 2021 Mar
TI  - Fasting reduces the incidence of vincristine-associated adverse events in dogs.
PG  - 61-68
LID - 10.1111/vco.12638 [doi]
AB  - Fasting has been shown to decrease chemotherapy-associated adverse events (AEs), 
      in part through insulin-like growth factor (IGF-1) reduction, and may induce a 
      protective effect on normal cells during chemotherapy treatment in mice and 
      people. The purpose of this study was to evaluate the effect of fasting on 
      constitutional, bone marrow and gastrointestinal (GI) AEs, and serum glucose, 
      IGF-1 and insulin levels in dogs receiving vincristine. The study was a 
      prospective, crossover clinical trial in tumour-bearing dogs. Dogs were 
      randomized to be fasted for 24 to 28 hours prior to and 6 hours following their 
      first or second vincristine treatment, and fed normally for the alternate dose. A 
      significant reduction in nausea, anorexia, lethargy and serum insulin was 
      observed when dogs were fasted; however, no significant differences were found in 
      other GI symptoms, neutrophil count, serum glucose or IGF-1. Fasting prior to 
      vincristine therapy is a safe and effective treatment modality that helped 
      mitigate constitutional and GI AEs in tumour-bearing dogs.
CI  - (c) 2020 The Authors. Veterinary and Comparative Oncology published by John Wiley & 
      Sons Ltd.
FAU - Duckett, Margaret E
AU  - Duckett ME
AUID- ORCID: 0000-0003-3820-1791
AD  - Department of Clinical Sciences, Carlson College of Veterinary Medicine, Oregon 
      State University, Corvallis, Oregon, USA.
FAU - Curran, Kaitlin M
AU  - Curran KM
AD  - Department of Clinical Sciences, Carlson College of Veterinary Medicine, Oregon 
      State University, Corvallis, Oregon, USA.
FAU - Leeper, Haley J
AU  - Leeper HJ
AUID- ORCID: 0000-0003-0900-0851
AD  - Department of Clinical Sciences, Carlson College of Veterinary Medicine, Oregon 
      State University, Corvallis, Oregon, USA.
FAU - Ruby, Carl E
AU  - Ruby CE
AD  - Department of Clinical Sciences, Carlson College of Veterinary Medicine, Oregon 
      State University, Corvallis, Oregon, USA.
FAU - Bracha, Shay
AU  - Bracha S
AD  - Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, 
      Texas, USA.
LA  - eng
PT  - Clinical Trial, Veterinary
PT  - Journal Article
DEP - 20200826
PL  - England
TA  - Vet Comp Oncol
JT  - Veterinary and comparative oncology
JID - 101185242
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Blood Glucose)
RN  - 0 (Insulin)
RN  - 5J49Q6B70F (Vincristine)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
SB  - IM
MH  - Animal Feed
MH  - Animals
MH  - Antineoplastic Agents/*adverse effects/therapeutic use
MH  - Blood Glucose/*drug effects
MH  - Bone Marrow/drug effects
MH  - Cross-Over Studies
MH  - Dog Diseases/*chemically induced/drug therapy
MH  - Dogs
MH  - Food Deprivation
MH  - Gastrointestinal Diseases/chemically induced/*veterinary
MH  - Insulin/blood/metabolism
MH  - Insulin-Like Growth Factor I/metabolism
MH  - Neoplasms/drug therapy/*veterinary
MH  - Vincristine/*adverse effects/therapeutic use
PMC - PMC7891372
OTO - NOTNLM
OT  - cancer
OT  - chemotherapy
OT  - dogs
OT  - fasting
OT  - toxicity
OT  - vincristine
COIS- The authors declare no conflicts of interest.
EDAT- 2021/01/16 06:00
MHDA- 2021/09/23 06:00
PMCR- 2021/02/18
CRDT- 2021/01/15 08:47
PHST- 2020/03/09 00:00 [received]
PHST- 2020/07/14 00:00 [revised]
PHST- 2020/07/15 00:00 [accepted]
PHST- 2021/01/16 06:00 [pubmed]
PHST- 2021/09/23 06:00 [medline]
PHST- 2021/01/15 08:47 [entrez]
PHST- 2021/02/18 00:00 [pmc-release]
AID - VCO12638 [pii]
AID - 10.1111/vco.12638 [doi]
PST - ppublish
SO  - Vet Comp Oncol. 2021 Mar;19(1):61-68. doi: 10.1111/vco.12638. Epub 2020 Aug 26.